



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/828,970	04/21/2004	Christopher P. Miller	WYTH0039-101 5396 (AM100787-D1 EXAMINER	
35139 75	90 06/13/2005			
COZEN O' CONNOR, P. C.			DENTZ, BERNARD I	
1900 MARKET STREET PHILADELPHIA, PA 19103-3508			ART UNIT	PAPER NUMBER
			1625	
			DATE MAILED: 06/13/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/828,970	MILLER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Bernard Dentz	1625			
The MAILING DATE of this communication appeariod for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
2a) This action is <b>FINAL</b> . 2b) ⊠ This	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	33 O.G. 213.			
Disposition of Claims					
4) ☐ Claim(s) 6-22 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 6-22 are subject to restriction and/or expressions.					
Application Papers					
9) The specification is objected to by the Examiner					
10)☐ The drawing(s) filed on is/are: a)☐ acce	• • •				
Applicant may not request that any objection to the o		• •			
Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Example 11.		` '			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa				

Application/Control Number: 10/828,970 Page 2

Art Unit: 1625

In the following Groups I-V restriction among benzofurans which are substituted with a 2-(4-oxyphenyl) group and a 5-oxy- group is based on the 7-position substituent. Below they will be denoted as B.

- I. Claim 6, drawn to B with hydrogen (i.e. unsubstituted at 7-), hydrocarbon or a halohydrocarbon moiety at 7, classified in class 549, subclass 467.
- II. Claim 6, drawn to B with a hydrocarbon group containing O or S singly bonded thereto at 7, classified in class 549, subclass 467.
  - III. Claim 6, drawn to B containing a group with a carbon double or triple bonded to a N, O or S atom at 7, classified in class 549, subclass 467.
  - IV. Claim 6, drawn to B containing amino, halogen, oxygen or nitro directly attached to 7, classified in class 549, subclass 467.
  - V. Claim 6, drawn to B containing a heteroaryl group directly attached at 7 as in o) and nnnnn), classified in class 548, subclass 143.
  - VI. Claim 6, drawn to benzofurans containing a 2-(4-oxy-phenyl) group and a hydroxymethyl, carboxy or carboxylic acid ester group in the 5-position as in rrrr) thru ttttt), classified in class 549, subclass 467.
  - VII. Claim 6, drawn to benzofurans containing a 4-hydroxymethyl- or 4-carboxy- or 4-methoxycarbonylphenyl group in the 2-position as eeeee), ccccc) and ddddd), classified in class 549, subclass 467.

Application/Control Number: 10/828,970

Art Unit: 1625

- VIII. Claim 6, drawn to benzofurans containing an acetyl group or its alcohol or oxime derivative in the 3-position as in nnnn), oooo) and pppp), classified in class 549, subclass 467.
- IX. Claim 6, drawn to biphenyl containing benzofurans as in iiii) to IIII), classified in class 549, subclass 467.
- X. Claim 6, drawn to benzofurans substituted at 5- with halo, alkyl or haloalkyl as in mmm) to bbbb) classified in class 549, subclass 467.
- XI. Claim 6, drawn to benzofuran boronic acid type compound jjj), classified Class 549, sub-class 213.
  - XII. Claim 6, drawn to benzaldehydes a), oo) and pp), classified in class 568, subclass 442.
  - XIII. Claim 6, drawn to 1,4-dimethoxybenzenes tt), ss) and rr), classified in class 558, subclass 410.
  - XIV. Claim 6, drawn to 1,2-di(substitutedphenyl)ethanones hhh), aaaaa) and uu), classified in class 568, subclass 331.
  - XV. Claim 6, drawn to 2-iodo-4-methoxy-6-nitrophenol cccc), classified in class 568, subclass 649.
  - XVI. Claim 10 drawn to a method of treating prostatitis.
  - XVII. Claim 11 drawn to a method of treating inflammatory bowel disease.
  - XVIII. Claim 12 drawn to a method of treating cancer, etc.
  - XIX. Claim 10 a method of lowering cholesterol.
  - XX. Claim 11- a method of cognition enhancement.

Application/Control Number: 10/828,970

Art Unit: 1625

XXI. Claim 12- a method of inhibiting free radicals.

XXII. Claim 13 -a method of inhibiting vaginal atophy.

XXIII. Claim 14-a method of inhibiting vasomotor symptoms.

XXIV. Claim 15- a method of inhibiting conception.

XXV. Claims 16-18- a method for inhibiting arthritis, etc.

XXVI. Claim 19- a method of treating psoriasis.

XXVII. Claim 20- a method of treating ischemia, etc.

XXVIII. Claim 21-a method of treating endometriosis.

XXIX. Claim 22- a pharmaceutical composition containing a compound of formula I. It is believed this is the subject of the last claim of applicants' US Patent 6,774,248.

. Benzofurans of many different types of substitution are present in aggregation of species claim 6 as well as different types of non-benzofuran compounds containing different functional groups and 1 or 2 phenyl moieties. Some of the directly above mentioned benzofurans are intermediates and some are final product intended pharmaceuticals. All of the non-benzofurans are intermediates. The multitude of methods of use are very diverse. If applicants pick one of these methods they should elect the one with the most enabling disclosure. Thus restriction of the above distinct and independent inventions which have different searches is proper.

Application/Control Number: 10/828,970 Page 5

Art Unit: 1625

In case one of the compound Gps. or generic method of use Gps. is elected, applicants should elect a single disclosed species in case no generic claim is found allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon.-Fri from 8 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached on 571 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dentz

6-8-2005

BERNARD DENTE RIMARY EXAMINER GROUP 1000